1. Home
  2. GOVX vs RDHL Comparison

GOVX vs RDHL Comparison

Compare GOVX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

BUY

Current Price

$0.28

Market Cap

3.0M

Sector

Health Care

ML Signal

BUY

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$0.53

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOVX
RDHL
Founded
2001
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.3M
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
GOVX
RDHL
Price
$0.28
$0.53
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $10.00
N/A
AVG Volume (30 Days)
814.4K
★ 869.5K
Earning Date
11-12-2026
09-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $2,489,145.00
N/A
Revenue This Year
N/A
$17,592.31
Revenue Next Year
N/A
$25.89
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.27
$0.44
52 Week High
$157.50
$2.14

Technical Indicators

Market Signals
Indicator
GOVX
RDHL
Relative Strength Index (RSI) 23.04 45.63
Support Level N/A N/A
Resistance Level $0.46 $1.07
Average True Range (ATR) 0.04 0.05
MACD 0.01 0.01
Stochastic Oscillator 7.65 34.96

Price Performance

Historical Comparison
GOVX
RDHL

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

About RDHL Redhill Biopharma Ltd.

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

Share on Social Networks: